CATANIA, Italy, Nov. 19, 2020 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its ...

CATANIA, Italy, Sept. 30, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announced that is has received a Notice of Allowance from the European Patent Office ("EPO") for ...

The treatment being studied, low concentration polihexanide (PHMB 0.02%), was first compounded and used in the 1990s to treat AK, introduced by a team co-led by this latest study's lead author, ...

Polihexanide 0.08% Exhibits Compelling Safety and Tolerability Characteristics in Healthy Volunteers CATANIA, Italy, Feb. 1, 2021 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ...

ACI SANT'ANTONIO, Italy, July 22, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company headquartered in Italy, is pleased to announce that the Committee for Orphan Medicinal Products ...

CATANIA, Italy, Feb. 1, 2021 /CNW/ -- SIFI, a leading ophthalmic company, announced today the publication of clinical results from its Phase I trial of polihexanide in healthy volunteers. The paper ...

CATANIA, Italy, Nov. 19, 2020 /CNW/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its pivotal ...